-->

Type something and hit enter

Pages

Singapore Investment


On

KANGER (0170) KANGER INTERNATIONAL BHD to distribute Sinopharm's Covid-19 testing solutions

Kanger International Bhd’s subsidiary Kanger Medical International Sdn Bhd enters into a heads of agreement (HoA) with Sparmak Medical Equipment Trading LLC to distribute Sinopharm’s Covid-19 testing solutions using OXLAMP technology in Malaysia.

KUALA LUMPUR: Kanger International Bhd's subsidiary Kanger Medical International Sdn Bhd has entered into a heads of agreement (HoA) with Sparmak Medical Equipment Trading LLC to distribute Sinopharm's Covid-19 testing solutions using OXLAMP technology in Malaysia.

Kanger will make an initial purchase of one million Covid-19 testing solutions and corresponding diagnostic devices, with deliveries expected to commence as soon as November.

Kanger executive director Joseph Wu Wai Kong said Sinopharm's testing solutions were used globally as a quick and effective way to detect Covid-19 cases.

"As the nation moves into the endemic phase and as domestic and international borders re-open, there will be a surge in demand for Covid-19 testing solutions which are fast, affordable and accurate," he said.

He said the OXLAMP testing method was easy to set up and did not need expensive equipment.

"Testing can be carried out on-site on a wide scale with results made available within 30 minutes. This way, the OXLAMP testing solutions will decentralise Covid-19 testing efforts across the country, allowing improved access and shorter turnaround times.

"This enables more people to get tested and curb the infection spread through early detection."

Kanger has identified the recovery of tourism activities as an attractive market potential.

The first batch of testing solutions can be swiftly deployed at airports, train stations and hotels to carry out wide and rapid testing of Covid-19.

Currently, travellers leaving and returning to Malaysia will need to conduct a polymerase chain reaction test of which results can take up three days to be made available

The testing devices are web enabled which will allow for results to be immediately uploaded to the relevant health apps and portals for easy and quick verification. This will result in simple and seamless process.

"We are optimistic that the testing solutions will be in high demand as it can be used across many sectors in Malaysia," he said.

"We will be applying for the Medical Device Authorisation as well as relevant approvals from regulatory authorities prior to distribution in Malaysia," he added.

The OXLAMP technology was developed at Oxford University and uses a simple viral ribonucleic acid (RNA) testing method, loop-mediated isothermal amplification (RT-LAMP) to detect fragments of the virus without professional instruments or training.

The test is done through a nasal swab collection with samples analysed at the point of collection enabling speedy results delivery.

https://www.nst.com.my/business/2021/10/740565/kanger-distribute-sinopharms-covid-19-testing-solutions

Back to Top